MRSN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 109825 min ago

@ $3.79

Wydano: 14 vas. 2024 @ 20:46

Zwrot: -16.36%

Poprzedni sygnał: vas. 14 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: -3.33 %

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	1.16M
Średni wolumen	2.23M
Kapitalizacja rynkowa	382.24M
EPS	$0 ( 2024-02-27 )
Następna data zysków	( $-0.180 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.800
ATR14	$0.00800 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Alleva Lawrence M	Buy	3 996	Stock Option (right to buy)
2024-01-13	Mandelia Ashish	Buy	0
2024-01-15	Protopapas Anna	Buy	17 708	Common Stock
2024-01-15	Protopapas Anna	Buy	21 250	Common Stock
2024-01-16	Protopapas Anna	Sell	29 399	Common Stock

INSIDER POWER
74.95
Last 98 transactions
Buy: 4 017 838 \| Sell: 585 969

Wolumen Korelacja

Długi: -0.35 (neutral)

Krótki: 0.28 (neutral)

Signal:(47.61) Neutral

Mersana Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mersana Therapeutics Inc Korelacja - Waluta/Towar

-0.79
( moderate negative )

-0.84
( strong negative )

0.00
( neutral )

-0.78
( moderate negative )

-0.90
( strong negative )

0.60
( weak )

Mersana Therapeutics Inc Finanse

Annual	2023
Przychody:	$36.86M
Zysk brutto:	$35.34M (95.88 %)
EPS:	$-1.480

FY	2023
Przychody:	$36.86M
Zysk brutto:	$35.34M (95.88 %)
EPS:	$-1.480

FY	2022
Przychody:	$26.58M
Zysk brutto:	$25.65M (96.51 %)
EPS:	$-2.22

FY	2021
Przychody:	$43 000.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.37

Financial Reports:

No articles found.

Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.